Brookline Capital Upgrades Dare Bioscience to Buy, Announces $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
Brookline Capital analyst Kemp Dolliver has upgraded Dare Bioscience (NASDAQ:DARE) from Hold to Buy and set a price target of $3.
May 15, 2024 | 10:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Brookline Capital has upgraded Dare Bioscience from Hold to Buy and set a price target of $3, indicating a positive outlook for the stock.
The upgrade from Hold to Buy and the new price target of $3 by Brookline Capital suggests increased confidence in Dare Bioscience's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100